These results provide not only evidence that validates targeting of PFKFB3 but also the first direct structural insight into the protein inhibitor interactions, establishing a foundation for structure-assisted optimization and development of novel PFKFB3 inhibitors as chemotherapeutic agents for cancer. This evidence concerns the gene PFKFB3 and cancer.